Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888
36.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
276.0
Breastfeeding should be discontinued if the mother is treated with indenoisoquinolines
74.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
30.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888 and SCH727965
130.0
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with vorinostat
40.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib; this may also apply to other agents used in this study
107.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this drug
132.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237
24.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
55.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
42.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD1775 (MK-1775)
36.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with XL184
72.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN8237 and/or romidepsin
42.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD2171
73.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with belinostat
80.0
Patients who are nursing infants: breastfeeding should be discontinued if the mother is treated with the study agents
70.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dabrafenib
18.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ALT-803
12.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with the study drugs
68.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with pomalidomide
63.0
Pregnant women are excluded from this study; breastfeeding should be discontinued prior to the mother being treated with the study drugs
32.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with this agent
40.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228) and ziv-aflibercept
57.0
Pregnant or nursing women; breastfeeding should be discontinued if the mother is treated with MLN0128
23.0
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
52.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
90.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with terameprocol
23.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
80.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with cabozantinib
135.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
37.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with talazoparib (BMN 673)
66.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449
12.0
Breastfeeding should be discontinued if the mother is treated with sEphB4-HSA
42.0
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128 (TAK-228)
209.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with TRC102
58.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
30.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with NT-I7
75.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MLN0128
30.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 and paclitaxel
33.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and necitumumab
82.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AZD9291 and navitoclax
50.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI-570
46.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with methoxyamine
15.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with erlotinib and onalespib
46.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide
36.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks may also apply to other agents used in this study
90.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970)
45.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with AT13387 (onalespib)
50.0
Pregnant and breastfeeding women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ibrutinib
32.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
46.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with M6620 (VX-970) and/or gemcitabine
70.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
29.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with VX-970
51.0
Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with VX-970; these potential risks also apply to the other agents used in this study, such as carboplatin and gemcitabine
150.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with any of these agents
48.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab
20.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with high dose nelfinavir
36.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated
38.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SGI-110
70.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with dasatinib
24.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
35.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with selumetinib
28.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
40.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with nivolumab and ipilimumab; these potential risks may also apply to blinatumomab
30.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab
60.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MEDI4736 (durvalumab), tremelimumab and radiation
180.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ipilimumab
48.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with atezolizumab and/or bevacizumab
22.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with BAL101553
30.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with IPdR
47.0
Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with PT2385
35.0
